Currentsierra health and lifePolicy 2025E0046S

Benlysta (belimumab) intravenous injection

Defines UnitedHealthcare commercial medical benefit coverage criteria, continuation criteria, exclusions, applicable billing codes, and authorization durations for benlysta (belimumab) intravenous infusion for treatment of systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Specifies that subcutaneous self-administered benlysta is pharmacy benefit unless exceptions apply.

Policy Summary

Payersierra health and life

PolicyBenlysta (belimumab) intravenous injection

Policy CodePolicy 2025E0046S

Change Typerevised (supporting info/refs updated)

Effective DateDec 1, 2025

Next Review Date

Key ActionInitial and continuation authorizations require documentation that all listed clinical criteria are met; authorizations are limited to no more than 12 months.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version 2025E0046R.

2Covered Indications

12 monthsAuth duration

J0490Relevant J-code

Coverage Summary

Defines UnitedHealthcare commercial medical benefit coverage for benlysta (belimumab) intravenous infusion for the treatment of systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Subcutaneous self-administered benlysta is obtained under the pharmacy benefit unless plan documents or specific delegated review for California plans specify otherwise.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

SLE - Initial Therapy (medically necessary)

Benlysta is proven and medically necessary for the treatment of systemic lupus erythematosus when ALL of the following criteria are met:

SLE - Initial Therapy

Diagnosis of active systemic lupus erythematosus, without severe active central nervous system lupus
Standard therapy: Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic
Concomitant therapies: Patient is not receiving Benlysta in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab-fnia)
Dosing: Benlysta is initiated and titrated according to US Food and Drug Administration labeled dosing for SLE
Authorization duration: Initial authorization is for no more than 12 months
Authorization duration limit

SLE - Continuation of Therapy (medically necessary)

For continuation of therapy, ALL of the following must be met:

SLE - Continuation

Prior receipt: Patient has previously received Benlysta injection for intravenous infusion
Clinical response: Documentation of positive clinical response
Standard therapy: Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic
Concomitant therapies: Patient is not receiving Benlysta in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab-fnia)
Dosing: Benlysta is dosed according to US Food and Drug Administration labeled dosing for SLE
Authorization duration: Authorization is for no more than 12 months
Authorization duration limit

Lupus Nephritis - Initial Therapy (medically necessary)

Benlysta is proven and medically necessary for the treatment of active lupus nephritis when ALL of the following criteria are met:

Lupus Nephritis - Initial Therapy

Diagnosis of active lupus nephritis, without severe active central nervous system lupus
Standard therapy: Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic
Concomitant therapies: Patient is not receiving Benlysta in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab-fnia)
Dosing: Benlysta is initiated and titrated according to US Food and Drug Administration labeled dosing
Authorization duration: Initial authorization is for no more than 12 months
Authorization duration limit

Lupus Nephritis - Continuation of Therapy (medically necessary)

For continuation of therapy, ALL of the following must be met:

Lupus Nephritis - Continuation

Prior receipt: Patient has previously received Benlysta injection for intravenous infusion
Clinical response: Documentation of positive clinical response
Standard therapy: Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic
Concomitant therapies: Patient is not receiving Benlysta in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab-fnia)
Dosing: Benlysta is dosed according to US Food and Drug Administration labeled dosing
Authorization duration: Authorization is for no more than 12 months
Authorization duration limit

Not Medically Necessary / Unproven

Benlysta is unproven and not medically necessary for the following indications:

Not Medically Necessary / Unproven (exclusion)

ANCA vasculitis: Antineutrophil cytoplasmic antibody-associated vasculitis
Rheumatoid arthritis
Severe CNS lupus: Severe active central nervous system (CNS) lupus
Sjögren's syndrome
Combination biologics: Use in combination with other biologics
Waldenström macroglobulinemia

Applicable Codes

J-code for belimumab intravenousHCPCS

J0490

Injection, belimumab, 10 mg

Relevant diagnosis codes (SLE / lupus nephritis)ICD-10

M32.0	Drug-induced systemic lupus erythematosus
M32.10	Systemic lupus erythematosus, organ or system involvement unspecified
M32.11	Endocarditis in systemic lupus erythematosus
M32.12	Pericarditis in systemic lupus erythematosus
M32.13	Lung involvement in systemic lupus erythematosus
M32.14	Glomerular disease in systemic lupus erythematosus
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus
M32.19	Other organ or system involvement in systemic lupus erythematosus
M32.8	Other forms of systemic lupus erythematosus
M32.9	Systemic lupus erythematosus, unspecified

Provider Actions

Prior Authorization

Prior authorization required for Benlysta IV

Initial and continuation prior authorization is required for Benlysta intravenous (IV). Authorizations (initial and continuation) require documentation that all listed clinical criteria in the policy are met and are limited to no more than 12 months.

J0490

Documentation Required

Document positive clinical response for continuation

For continuation of therapy, the provider must document that the patient previously received Benlysta IV and that the patient has demonstrated a positive clinical response.

Billing Rule

Benefit determination and site-of-care note

Benlysta IV (intravenous belimumab) is addressed under the medical benefit. Self-administered subcutaneous Benlysta is obtained under the pharmacy benefit unless the member's benefit plan documents or a specific delegated prior authorization review (for UnitedHealthcare of California plans) specify otherwise.

J0490
Exception: For members enrolled in UnitedHealthcare of California plans with a delegated provider group conducting the prior authorization review, self-administered subcutaneous Benlysta may be obtained under the medical benefit.

Clinical Evidence

placebo 29% vs belimumab 46%SRI response at Week 52 (autoantibody-positive patients); p < 0.05

PERR higher with belimumabLupus nephritis Primary Efficacy Renal Response (PERR) at Week 104: proportion achieving PERR was significantly higher with belimumab plus standard therapy vs placebo plus standard therapy

Clinical evidence includes improved SLE responder outcomes in adult trials: in autoantibody‑positive patients at Week 52 the SLE Responder Index (SRI) was placebo 29% vs belimumab 46% (p < 0.05) with long‑term maintenance of responses and reductions in flares and corticosteroid use over extended follow‑up.

In lupus nephritis, a 104‑week randomized, double‑blind, placebo‑controlled trial of IV belimumab 10 mg/kg plus standard therapy demonstrated a significantly higher proportion of patients achieving the trial’s Primary Efficacy Renal Response (PERR) at Week 104 compared with placebo plus standard therapy, and a lower risk of renal‑related event or death.

Definitions used in trial context and the policy: Standard therapy refers to antimalarials, corticosteroids, or immunosuppressants that are not biologics (e.g., mycophenolate, cyclophosphamide, azathioprine as used in trials).

PERR (Primary Efficacy Renal Response) is defined in the lupus nephritis trial as uPCR ≤ 0.7 g/g and eGFR ≥ 60 mL/min/1.73 m2 or no decrease in eGFR of > 20% from pre-flare value, confirmed at Week 104.

Background

Belimumab is a recombinant human IgG1 λ monoclonal antibody that binds soluble B‑lymphocyte stimulator (BLyS/BAFF), blocking BLyS binding to B‑cell receptors and thereby inhibiting B‑cell survival and differentiation into immunoglobulin‑producing plasma cells.

Indication statement: Benlysta is indicated for patients aged 5 years and older with active systemic lupus erythematosus who are receiving standard therapy and for patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.

Policy background and application: the policy addresses the IV formulation administered per FDA‑labeled dosing and specifies that efficacy in severe active CNS lupus has not been established (limitation of use).